checkAd

     105  0 Kommentare Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology - Seite 3

    FORWARD-LOOKING STATEMENTS

    This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

    Media Contact Evotec SE:
    Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

    IR Contact Evotec SE:
    Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com

    SOURCE: Evotec AG



    View source version on accesswire.com:
    https://www.accesswire.com/702001/Evotec-and-Almirall-Enter-into-a-Mul ...

    Seite 3 von 3


    Der Analyst erwartet ein Kursziel von 10,73, was eine Steigerung von +4,44% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.
    Übernehmen
    Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
    Bitte verändern Sie Kursziel, Zeitraum oder Emittent.
    Alternativ können Sie auch unsere Derivate-Suchen verwenden
    Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche
    WerbungDisclaimer

    Diskutieren Sie über die enthaltenen Werte



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Evotec and Almirall Enter into a Multi-Target Alliance in Medical Dermatology - Seite 3 THE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS BASAL CELL CARCINOMATHE COLLABORATION …

    Schreibe Deinen Kommentar

    Disclaimer